近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1. Nashan B, Schlitt H J, Tusch G, Oldhafer K, Ringe B, Wagner S, Pichlmayr R. Biliarymalignancies in primary sclerosing cholangitis. Timing for liver transplantation. Hepatology 1996. 23:1105-11 2. Nashan B, Schlitt H J, Schwinzer R, Ringe B, Kuse E, Tusch G, Wonigeit K, Pichlmayr R.Immunoprophylaxis with a monoclonal anti IL-2 receptor antibody in liver transplantedpatients. Transplantation 1996; 61:546-54 3. Nashan B, Moore R, Amlot P, A G Schmidt, K Abeywickrama, J P Soulillou. Randomisedtrial of basiliximab versus placebo for control of acute cellular rejection in renal allograftrecipients. The Lancet 1997; 350:1193-8. 4. Nashan B, Light S, Hardie IR, Lin A, Johnson R. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67:110-5. 5. Neipp M, G Offner G, R Lück R, Ehrich JHH, Strehlau J, Schlitt H J, Klempnauer J, Nashan B. Kidney transplantation in small children: Donor selection and technical consideration. Transplantation. 2002; 73: 409-16. 6. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T on behalf of the 156 StudyGroup. Everolimus in Combination with Reduced-Exposure Cyclosporine in de novo RenalTransplant. Recipients: Results of a 3-Year Phase II, Randomized, Multicenter, Open- Label Study. Transplantation 2004; Nov 15;78(9):1332-40. 7. Neipp M, Jackobs S, Becjer T, Lueck R, Meyer zu Vilsendorf A, Winny M, Klempnauer J, Nashan B. Living Donor Nephrectomy: Flank Incision vs. Anterior Vertical Mini-Incision. Transplantation 2004; 15;78(9):1356-61. 8. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lan P, Grinyo J, Halloran P F, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; BelataceptStudy Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353:770-81. 9. Frericks BB, Kirchhoff TD, Shin H O, Stamm G, Merkesdal S, Abe T, Schenk A, Peitgen HO, Klempnauer J, Galanski M, Nashan B. Preoperative volume calculation of the hepaticvenous draining areas with multi-detector row CT in adult living donor liver transplantation: impact on surgical procedure. Eur Radiol. 2004 Feb;14(2):326-33. 10. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75. 11. Nashan B, Saliba F, Durand F, Barcéna R, Herrero J I, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives, R J Mamelok, D Mc Kay, M Truman, P Marotta. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl. 2009 Feb;15(2):136-47. 12. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran P F, Klempnauer J, Lang P, Larsen C P, Mühlbacher F, Nashan B, Soulillou J P, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi v, Shen J, R Shi R, Townsend R, Charpentier B. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010. Sep;21(9):1587-96. PMID:20634298 13. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011 Jul;11(7):1444-55. 14. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012 Nov 20;11:85. 15. Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 2013 Apr 16. 16. David KA, Unger FT, Uhlig P, Juhl H, Moore HM, Compton C, Nashan B, Dörner A, de Weerth A, Zornig C. Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue. Oncotarget. 2014 Nov 30;5(22):11017-28. doi: 10.18632/oncotarget.2669. 17. Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker, M. Dual Inhibition of PI3K- AKT-mTOR- and RAF-MEK-ERK-signalling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs. 2014 Dec;32(6):1144- 54. doi: 10.1007/s10637-014-0149-7. 18. Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, Jücker M, Ewald F. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cell Signal. 2015 Jul 22. pii: S0898-6568(15)00213-2. doi:10.1016/j.cellsig.2015.07.016. 19. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - arandomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0.
京公网安备 11010802027423号